<p>(a) Fluorescence (FL) and bright field (BF) micrographs of HER2-positive N87 cells treated with sfGFP, mH1, mH2, mH3, mH4, and mH5 for 16 h. Exposure time = 1/200 s. Bar = 50 µm. (b) FL and BF micrographs of HER2-positive N87 cells treated with sfGFP, mH1C, mH2C, mH3C, mH4C, and mH5C for 16 h. Exposure time = 1/200 s or 1/2 s. Bar = 50 µm.</p
<p>(A) The binding activity of Fab-KZ52 to GP was evaluated in ELISA experiments where a layer of an...
<p>(a) 5 nM pure G3-SNAP conjugates and 5 nM unpurified G3-SNAP conjugates were separately used in i...
<p>To determine the interaction of HRG1β with HER3 in presence and absence of anti-HER3 antibody mAb...
<p>A) Spot density/µm<sup>2</sup> plot for HER1 Affibody Alexa488 on T47D cells in presence (red) or...
<p>(A–C) Images from an agglutination assay using GM1-Glc-SFNPs and serum from a GBS patient after i...
<p>A. BT-474 cells were incubated for one hour with increasing concentration of Z<sub>HER2</sub>-GSC...
68Ga-RM2 and 18F-FDG bindings in breast cancer samples according to biological data.</p
Human epidermal growth factor receptor type 2 (HER2) is a well-known biomarker that is overexpressed...
<p>(A) ELISA reactivity of gBs to anti-gB mAb. gBs or HA, as a negative control, was immobilized on ...
Representative GRP-R IHC (A; GRPR-IHC), HES staining (B; HES, black lines correspond to tumoral area...
Cell binding assay of ErbB2 aptamers using flow cytometry and fluorescence spectroscopy (A) The spec...
<p>(A) 100 nM FITC-monomeric and heptameric Z<sup>EGFR</sup> ligands were used for labeling of EGFR ...
<p>(A) Expression of HER1 and HER2 in N87-GFP cells was examined with FACS. HER2 was overexpressed m...
<p>A) EGF-Alexa 488, B) EGF-Alexa 546, C) EGF-Atto 647N, D) anti-HER2 Affibody-Alexa 488, E) anti-HE...
<p>(a) Bright field (BF) and fluorescence (FL) micrographs of yeast cells harboring empty control (p...
<p>(A) The binding activity of Fab-KZ52 to GP was evaluated in ELISA experiments where a layer of an...
<p>(a) 5 nM pure G3-SNAP conjugates and 5 nM unpurified G3-SNAP conjugates were separately used in i...
<p>To determine the interaction of HRG1β with HER3 in presence and absence of anti-HER3 antibody mAb...
<p>A) Spot density/µm<sup>2</sup> plot for HER1 Affibody Alexa488 on T47D cells in presence (red) or...
<p>(A–C) Images from an agglutination assay using GM1-Glc-SFNPs and serum from a GBS patient after i...
<p>A. BT-474 cells were incubated for one hour with increasing concentration of Z<sub>HER2</sub>-GSC...
68Ga-RM2 and 18F-FDG bindings in breast cancer samples according to biological data.</p
Human epidermal growth factor receptor type 2 (HER2) is a well-known biomarker that is overexpressed...
<p>(A) ELISA reactivity of gBs to anti-gB mAb. gBs or HA, as a negative control, was immobilized on ...
Representative GRP-R IHC (A; GRPR-IHC), HES staining (B; HES, black lines correspond to tumoral area...
Cell binding assay of ErbB2 aptamers using flow cytometry and fluorescence spectroscopy (A) The spec...
<p>(A) 100 nM FITC-monomeric and heptameric Z<sup>EGFR</sup> ligands were used for labeling of EGFR ...
<p>(A) Expression of HER1 and HER2 in N87-GFP cells was examined with FACS. HER2 was overexpressed m...
<p>A) EGF-Alexa 488, B) EGF-Alexa 546, C) EGF-Atto 647N, D) anti-HER2 Affibody-Alexa 488, E) anti-HE...
<p>(a) Bright field (BF) and fluorescence (FL) micrographs of yeast cells harboring empty control (p...
<p>(A) The binding activity of Fab-KZ52 to GP was evaluated in ELISA experiments where a layer of an...
<p>(a) 5 nM pure G3-SNAP conjugates and 5 nM unpurified G3-SNAP conjugates were separately used in i...
<p>To determine the interaction of HRG1β with HER3 in presence and absence of anti-HER3 antibody mAb...